依达拉奉治疗急性脑梗塞疗效观察  

EDARAVONE IN TREATMENT OF ACUTE CEREBRAL INFARCTION AND CLINICAL OBSERVATION OF HS-CRP INFLUENCE

作　　者：凌文通[1] 徐嘉贺[1] 李建伟[1] 吴文军[1] 

机构地区：[1]中山市人民医院,广东中山528400

出　　处：《现代医院》2011年第7期59-60,共2页Modern Hospitals

摘　　要：目的了解依达拉奉对急性脑梗塞的治疗疗效及其对血清超敏C反应蛋白(hs-CRP)浓度的影响。方法选择我院2010年6月～2011年5月住院治疗的急性脑梗塞病人28例为治疗组,应用依达拉奉治疗;同时期住院治疗的急性脑梗塞26例为对照组,应用小牛血去蛋白血清治疗,观察两者的疗效并比较两组病人血清超敏C反应蛋白。结果治疗组疗效明显优于对照组,治疗组总有效率为78.57%,对照组总有效率为63.08%,两组比较结果有统计学意义(p<0.05);治疗组血清超敏C反应蛋白于治疗2周后其下降水平均明显优于对照组,两组比较差异具有统计学意义(p<0.05)。结论依法拉奉是一种新型的自由基清除剂和抗氧剂,是治疗急性脑梗塞很有效的药物。其对脑神经有修复保护作用。另外依达拉奉具有抑制损伤后炎症反应的作用,且于临床应用中未见有不良反应,症明其中安全有效的。Objective To observe edaravone in treatment of acute cerebral infarction and high sensitivity C -reactive protein. Methods There were 28 patients with acute cerebral infarction be chosen as treatment group in our hospital during June 2010 to May 2011, which be treated with edaravone; At the same time there were 26 patients with acute cerebral infarction be chosen as control group in our hospital, which be applied with deproteinized calf blood serum, observe the curative effect of those two group, contrasted the level of high sensitivity C - reactive protein. Results There were statistical significance between those two groups, the total effective rate in the treatment group is 92. 86%, the control group is 73. 08%, （the P value under 0. 05）. the high sensitivity C -reactive protein in treatment group has a distinct decline after 2 weeks treatment, there were statistical significance between those two groups, （ the P value under 0. 05）. Conclusion The edaravone is a kind of neuroprotection drugs in the treatment of acute cerebral infarction been proved very effective. Edaravone have the ability to inhibit inflammation and brain protection, edaravone be used as to heal cerebral infarction is safe and effective.

关 键 词：依达拉奉 急性脑梗塞 血清超敏 C反应蛋白 

分 类 号：R743.33[医药卫生—神经病学与精神病学]